The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Value Of The Chronic Liver Diseases Therapeutics Market Projected To Expand During 2026–2030?
The market size for chronic liver diseases therapeutics has experienced swift growth in recent years. It is anticipated to expand from $15.88 billion in 2025 to $17.56 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.6%. The historical surge can be linked to several factors, including improved diagnosis of chronic liver conditions, expansion of antiviral therapy usage, increased management of autoimmune liver diseases, wider access to hospital-based liver care, and the growth of specialty hepatology services.
The market for therapeutics addressing chronic liver diseases is projected to experience substantial expansion in the coming years. This market is anticipated to reach a valuation of $25.99 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.3%. Factors contributing to this growth during the forecast timeframe include greater investments in therapies for NASH and fibrosis, an increasing need for precision liver medicine, the broader availability of biologic and targeted treatments, an enhanced emphasis on early intervention strategies, and elevated clinical trial activities related to liver diseases. Key trends anticipated within the forecast period encompass the heightened development of targeted liver therapies, a greater concentration on treatment approaches specific to individual diseases, the wider embrace of combination drug regimens, the growth of non-invasive methods for disease monitoring, and an intensified focus on decelerating the progression of liver diseases.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21145&type=smp
Which Significant Factors Are Encouraging Growth In The Chronic Liver Diseases Therapeutics Market?
The chronic liver disease therapeutics market is projected to grow, propelled by the rising consumption of alcohol. Alcohol consumption refers to the intake of beverages containing ethanol, ranging from moderate to heavy use, which can have significant health impacts. This increase in alcohol consumption is fueled by factors such as growing social acceptance, higher incomes, and enhanced accessibility across the globe. Chronic liver disease therapeutics play a crucial role in managing liver damage caused by excessive alcohol intake, helping to slow the progression of the disease and improve liver function. For instance, in June 2024, data from the US financial institution First Citizens Bank revealed a 1.2% increase in direct-to-consumer (DTC) wine case sales in 2023 compared to 2022. Additionally, a report published in December 2023 by Kirin Holdings Company Limited, a Japan-based beverage company, indicated that roughly 192.1 million kiloliters of beer were consumed in 2022, representing a 2.9% increase from the prior year. Consequently, the increasing alcohol consumption is a key driver for the expansion of the chronic liver disease therapeutics market.
How Are Different Segment Groups Identified Within The Chronic Liver Diseases Therapeutics Market?
The chronic liver diseases therapeutics market covered in this report is segmented –
1) By Treatment Type: Antiviral Drugs, Immunosuppressants Vaccines, Immunoglobulins, Corticosteroids, Targeted Therapy, Chemotherapy
2) By Disease Type: Hepatitis, Autoimmune Diseases, Non-Alcoholic Fatty Liver Disease, Cancer, Genetic Disorders
3) By Application: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Antiviral Drugs: Nucleoside Or Nucleotide Analogues, Interferons, Direct-Acting Antivirals
2) By Immunosuppressants Vaccines: Calcineurin Inhibitors, mTOR Inhibitors, Purine Synthesis Inhibitors
3) By Immunoglobulins: Hepatitis B Immune Globulin, Intravenous Immunoglobulin
4) By Corticosteroids: Prednisolone, Methylprednisolone, Dexamethasone
5) By Targeted Therapy: Tyrosine Kinase Inhibitors, Monoclonal Antibodies
6) By Chemotherapy: Systemic Chemotherapy, Transarterial Chemoembolization Agents
What Trends Are Driving Changes In The Chronic Liver Diseases Therapeutics Market?
Leading firms within the chronic liver disease therapeutics market are concentrating on creating novel therapies, including engineered autologous macrophage cell therapy, aimed at improving liver regeneration, slowing fibrosis advancement, and offering more specific, disease-modifying treatment alternatives. This specific cell therapy involves utilizing a patient’s own macrophages, which are genetically altered or functionally improved externally before being reinfused into the body to diminish liver inflammation, encourage tissue healing, and either decelerate or reverse fibrosis associated with chronic liver conditions. An illustrative instance occurred in June 2024, when Resolution Therapeutics Ltd., a biotechnology company based in the UK, obtained authorization from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate its Phase I/II EMERALD study for their primary candidate, RTX001, which is intended for decompensated liver cirrhosis.
Who Are The Key Market Participants In The Chronic Liver Diseases Therapeutics Market?
Major companies operating in the chronic liver diseases therapeutics market are F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Novo Nordisk A/S, Dr. Reddy’s Laboratories Ltd., Vir Biotechnology Inc., Alnylam Pharmaceuticals Inc., Indian Immunologicals Limited, Intercept Pharmaceuticals Inc., Viking Therapeutics Inc., Ascletis Pharma Inc., Ochre Bio Limited, Tiziana Life Sciences Ltd., Antios Therapeutics Inc.
Access The Complete Chronic Liver Diseases Therapeutics Market Report:
Which Region Leads The Chronic Liver Diseases Therapeutics Market By Size?
North America was the largest region in the chronic liver diseases therapeutics market in 2025. The regions covered in the chronic liver diseases therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Chronic Liver Diseases Therapeutics Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=21145&type=smp
Browse Through More Reports Similar to the Global Chronic Liver Diseases Therapeutics Market 2026, By The Business Research Company
Kidney Disease Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/kidney-disease-global-market-report
Diabetic Kidney Disease Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/diabetic-kidney-disease-global-market-report
Late Stage Chronic Kidney Disease Drugs Global Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model